Bicalutamide is a non-steroidal anti-androgen used primarily to support the treatment of prostate cancer. It belongs to the men’s health and oncology support category and is available in a 50 mg oral pill formulation. In Hong Kong, bicalutamide is a prescription-only medication regulated by the Department of Health. The drug is also approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for similar indications.
Bicalutamide blocks the androgen receptor, preventing testosterone and its more potent metabolite dihydrotestosterone (DHT) from binding to target cells. By inhibiting this signaling pathway, the drug reduces the growth stimulus for prostate cancer cells that rely on androgen activation. Key pharmacologic points include:
Bicalutamide is FDA- and EMA-approved for:
In Hong Kong, the same indications are accepted under the local oncologic guidelines. The medication is not indicated for benign prostatic hyperplasia (BPH) or hormonal therapy in women.
Off-label applications require careful medical supervision and a risk-benefit assessment by a qualified provider.
Patients should disclose all medications, supplements, and herbal products to their prescribing clinician before starting bicalutamide.
Dosing adjustments for hepatic impairment should follow the prescribing information and be individualized by the treating oncologist.
This article provides educational information about bicalutamide and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, bicalutamide can be carried in its original labeled container. Upon arrival, you may be asked to present a copy of the prescription or a physician’s letter, especially if traveling to countries with strict drug-import regulations.
Standard occupational drug screens do not test for bicalutamide. However, elite sports agencies may screen for prohibited substances; anti-androgens are listed under certain doping regulations, so athletes should verify with their governing body.
In most markets, the 50 mg tablet is white, round, and may bear the imprint “BIC 50”. In other regions, appearance can vary slightly due to manufacturer differences.
All bicalutamide sold in Hong Kong must meet the standards of the Department of Health, ensuring consistent potency, purity, and labeling regardless of the manufacturing origin.
Bicalutamide received FDA approval in 1995 and has been incorporated into standard androgen-deprivation regimens for over two decades, with extensive post-marketing safety data.
Calcium does not interfere with the absorption or metabolism of bicalutamide, so concurrent use is generally considered safe.
Severe or rapidly worsening gynecomastia warrants prompt evaluation by your oncologist; radiation therapy or surgical options may be discussed if the discomfort is significant.
Yes, several manufacturers produce generic bicalutamide tablets that contain the same active ingredient and dosage strength as the branded product.
Generic bicalutamide is typically less expensive than newer anti-androgen agents such as enzalutamide or apalutamide, but exact pricing varies by pharmacy and insurance coverage.
If the organizer is airtight and protects the tablets from moisture, short-term storage (a few days) is acceptable. For longer periods, keep the medication in its original container to maintain stability.
